Document:

EXHIBIT 4.2

NEOSE TECHNOLOGIES, INC.

BOARD RESOLUTIONS
 AMENDMENT OF SHAREHOLDER RIGHTS PLAN

December 3, 1998

                    RESOLVED, that, pursuant to and in accordance with Section 26 of the Rights Agreement dated as of September 26, 1997 between the Company and American Stock Transfer & Trust Company, as Rights Agent (the “Rights Agent”),  the Board of Directors hereby deems it advisable to amend such agreement, and that the Amended and Restated Rights Agreement dated as of December 3, 1998 between the Company and the Rights Agent (as so amended and restated, the “Amended and Restated Rights Agreement”), substantially in the form presented to the Board of Directors, is hereby approved.

                    RESOLVED, that the Chairman of the Board, the Chief Executive Officer, the President, any Vice President and any other appropriate officers of the Company are hereby authorized to execute and deliver the Amended and Restated Rights Agreement, substantially in the form  presented to the Board of Directors, with such modifications as the officer so acting determines with the advice of counsel to be in the best interests of the Company, such determination to be conclusively evidenced by his execution and delivery of the Amended and Restated Rights Agreement.

                    RESOLVED, that the appropriate officers of the Company are hereby authorized, subject to the terms of the Amended and Restated Rights Agreement, to take any or all of the following actions on behalf of the Company:

             
                 (1) 
To file with the Securities and Exchange Commission and all appropriate agencies
of any State or States of the United States of America, a Registration Statement
or Statements, any related Prospectus or Prospectuses, a Current Report on Form
8-K, any application or applications, any report or reports and any other papers
and instruments with respect to the Amended and Restated Rights Agreement, such
documents to be in such form as may be approved by the officer or officers
executing any of the foregoing, whose execution thereof shall be conclusive
evidence of such approval, and to file amendments or supplements to any of the
foregoing and to take all such further action (including, without limitation,
the preparation and filing of one or more Registration Statements, or of
amendments to existing Registration Statements, relating to shares of Common
Stock of the Company to be issued pursuant to the Company’s 1995 Stock
Option/Stock Issuance Plan and any other employee benefit plan of the Company
and the execution and filing of all requisite surety bonds and irrevocable
consents and appointments of attorneys for service of process) as the officer so
acting may deem necessary, desirable or appropriate so that the foregoing shall
become effective;

              
                (2) 
To adopt on behalf of the Board of Directors the form of any resolution required
by any authority to be filed in connection with any applications, consents to
service, issuer’s covenants or other documents if (a) in the opinion of the
officers executing the same, with the advice of counsel, the adoption of such
resolutions is necessary, appropriate or desirable, and (b) the Secretary or an
Assistant Secretary evidences such adoption by inserting in the minute book of
the Company following the minutes of this meeting copies of such resolutions,
which will thereupon be deemed to have been adopted by this Board of Directors
with the same force and effect as if presented at this meeting;

            
                  (3) 
To execute such other certificates, instruments and documents and take such
action as may be necessary, desirable or appropriate in connection with the
Amended and Restated Rights Agreement as the acting officer or officers deem
appropriate; and 

        
                      (4) 
To take or cause to be taken any and all such further actions and to execute and
deliver or cause to be executed and delivered any and all such other
applications, certificates, documents, agreements and other instruments,
including without limitation indemnity agreements (as such may be required by
any stock exchange), and to incur and pay all such fees and expenses as, in the
judgment of the officer or officers so acting, may be necessary, desirable or
appropriate to carry into effect the purpose and intent of this and any and all
of the foregoing resolutions.

-2-EXHIBIT 10.45

Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.  Such portions are marked by a series of asterisks.

October 12, 2004

BY FAX and FEDERAL EXPRESS

Neose Technologies Inc.
 102 Witmer Road
 Horsham, PA 19044  
 USA

Attention: Head of Business Development 
 Fax: + 1 215-315 9100

Attention: General Counsel
 Fax: + 1 215-315 9100

	
  
Re:
  	
  
Research,   Development and License Agreement Among Neose Technologies, Inc. and Novo   Nordisk A/S and Novo Nordisk Health Care AG dated as of November 17, 2003, as   amended by letter agreement of December 18, 2003 (the “Agreement”) (relating   to ******)
  

Ladies and Gentlemen:

The purpose of this letter is to amend the Agreement in certain respects to reflect our recent discussions.  Capitalized terms used and not otherwise defined in this letter are used as defined in the Agreement. 

	
   
  	
  
1.
  	
  
Section 3.2   of the Agreement is hereby amended and restated in its entirety as follows:
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	

Milestone Payments Relating to Development of the New Product.  In consideration of the development   efforts of Neose under the Work Plan, Novo shall pay Neose the amount of each   milestone payment set forth in this Section 3.2 with respect to the   development of the New Product.  With   respect to the milestone payment described in Section 3.2.0, the   Parties agree that Neose shall 
  

 ****** — Material has been omitted and filed separately with the Commission.

Neose Technologies, Inc.
 October 12, 2004
 Page 2

	
  
 
  	
  
 
  	
  
have earned   the right to receive the milestone payment, and Novo shall be obligated to   pay the milestone payment and shall have met its diligence obligations with   respect to that milestone, as a result of the achievement of the milestone   event.  With respect to the milestone   payments described in Sections 3.2.1 through 3.2.7,  the Parties agree that Neose shall have   earned the right to receive a milestone payment, and Novo shall be obligated   to pay the milestone payment and shall have met its diligence obligations   with respect to the milestone, in each case, as a result of either (i) the   achievement of the milestone event prior to the occurrence of the   corresponding anniversary date or (ii) the occurrence, alone, of the   corresponding anniversary date.
  
	
   
  	
  
 
  	
  
 
  
	
  
 
  	
  
2.
  	
  
A new   Section 3.2.0 shall be added before Section 3.2.1 of the Agreement as   follows:
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
****** for   the achievement of ******, defined as ****** of New Product ****** in ******   when compared to Novo Materials ****** as follows: ****** and the ****** of   New Product ******, using the ****** attached hereto, entitled:  ******. The New Product and Novo Materials   will be administered in ******.
  

This letter amends the Agreement only as herein set forth and in all other respects the Agreement is ratified and confirmed.  Three originals of this letter amendment are enclosed in our Federal Express package, each of which has been executed on behalf of Novo Nordisk A/S and Novo Nordisk Health Care AG. Please indicate the agreement of Neose with the terms of this letter by having this letter executed on behalf of the company in the space provided below, and return two fully executed copies to Novo Nordisk A/S by fax (+ 45 44 42 18 30) and Federal Express or DHL courier (each to the attention of Jannie Fuhlendorff, Scientific Licensing).

Sincerely yours,

Jannie Fuhlendorff
 Scientific Licensing
 Novo Nordisk A/S

 ****** — Material has been omitted and filed separately with the Commission.

Neose Technologies, Inc.
 October 12, 2004
 Page 3

	
  
ACCEPTED AND   AGREED:
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  
	
  
NEOSE TECHNOLOGIES INC.
  	
  
 
  	
  
NOVO NORDISK A/S
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
   
  	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
By:
  	
  
/s/ ROBERT I. KRIEBEL
  	
  
 
  	
  
By:
  	
  
/s/ MADS KROGSGAARD THOMSEN
  
	
  
 
  	
  

  	
  
 
  	
  
 
  	
  

  
	
  
Name:
  	
  
Robert I.   Kriebel
  	
  
 
  	
  
Name: 
  	
  
Mads   Krogsgaard Thomsen
  
	
  Title:
  	
  
Senior Vice   President & CFO
  	
  
 
  	
  
Title:
  	
  
Executive   Vice President
  
	
  
November 9,   2004
  	
  
 
  	
  
 
  	
  
 
  
	 	 	 	 
	
  
 
  	
  
 
  	
  
 
  	
  
NOVO NORDISK HEALTH   CARE AG
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  	
  
By:
  	
  
/s/ KLAUS EHRLICH
  
	
   
  	
   
  	
   
  	
   
  	
  

  
	
   
  	
   
  	
   
  	
  Name:
  	
  Klaus   Ehrlich
  
	
   
  	
   
  	
   
  	
  Title:
  	
  Senior Vice   President
  

******

******

 ****** — Material has been omitted and filed separately with the Commission.EXHIBIT 10.46

Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.  Such portions are marked by a series of asterisks.

October 12, 2004

BY FAX and FEDERAL EXPRESS

Neose Technologies Inc.
 102 Witmer Road
 Horsham, PA 19044
 USA

Attention: Head of Business Development 
 Fax: + 1 215-315 9100

Attention: General Counsel
 Fax: + 1 215-315 9100

	
  
Re:
  	
  
Research,   Development and License Agreement Between Neose Technologies, Inc. and Novo   Nordisk A/S dated as of November 17, 2003, as amended by letter agreement of   December 18, 2003 (the “Agreement”) (******)
  

Ladies and Gentlemen:

The purpose of this letter is to amend the Agreement in certain respects to reflect our recent discussions.  Capitalized terms used and not otherwise defined in this letter are used as defined in the Agreement. 

	
   
  	
  
1.
  	
  
In   accordance with Sections 2.2 and 2.3.1, the Parties wish to amend the   Work Plan to reflect changes in the development of the New ******   Product.  Exhibit 2.2 to the Agreement   is hereby deleted and is replaced in its entirety by the Exhibit 2.2 attached   to this letter (the “Amended Exhibit 2.2”), which is hereby appended to and   incorporated into the Agreement.
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
2.
  	
  
Novo has   paid Neose an ****** in the amount of ****** under the Agreement and the   ****** Agreement (the “******”).  The   Parties agree that Neose shall ****** the ******, but that the ****** shall   be ****** under the Agreement, as hereby amended, in respect of the new   ****** Product ****** outlined in the Amended Exhibit 2.2 and any other   ****** Product ****** that are mutually agreed upon between the Parties,   included in a further amended Exhibit 2.2, and 
  

 ****** — Material has been omitted and filed separately with the Commission.

Neose Technologies, Inc.
 October 12, 2004
 Page 2

	
  
 
  	
  
 
  	
  
completed   prior to ******.  If and to the extent   that such ****** has not ****** by ****** and unless otherwise agreed upon by   the Parties in a subsequent amendment of the Agreement, Neose may ****** any   ****** and Neose shall be entitled to terminate the Agreement with respect to   the New ****** Product only, effective upon thirty (30) days written notice   to Novo.
  
	
   
  	
  
 
  	
  
 
  
	
  
 
  	
  
3.
  	
  
Section 3.2   of the Agreement is hereby amended and restated in its entirety as follows:
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
Milestone Payments Relating to Development of the New ****** Product.  In consideration of the development   efforts of Neose under the Work Plan, Novo shall pay Neose the amount of each   milestone payment described in this Section 3.2 with respect to the   development of the New ****** Product.    With respect to the milestone payments described in Sections 3.2.1   through 3.2.5, the Parties agree that Neose shall have earned the right   to receive each respective milestone payment, and Novo shall be obligated to   pay the milestone payment and shall have met its diligence obligations with   respect to the respective milestone, in each case, as a result of either (i)   the achievement of the milestone event prior to the occurrence of the   corresponding anniversary date or (ii) the occurrence, alone, of the   corresponding anniversary date.  With   respect to the milestone payments described in Sections 3.2.6 through
3.2.9, Neose shall have earned the right to receive each respective   milestone payment, and Novo shall be obligated to pay the milestone payment,   as a result of the of the achievement of the milestone event.
  
	
   
  	
  
 
  	
  
 
  
	
  
 
  	
  
4.
  	
  
Section   3.2.1 of the Agreement is hereby amended and restated in its entirety as   follows:
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
****** upon   the ****** to occur of (i) first date on which there shall be a candidate   which has been shown to meet the ****** for the New ****** Product, and Neose   shall have delivered to Novo ****** for the production of such candidate; and   (ii) ******.
  
	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
5.
  	
  
The Parties   acknowledge and agree that they may mutually determine to extend the date set   forth in clause (ii) of Section 3.2.1 (as set forth above) until ******   through a further amendment of the Agreement, without any ******, provided,   however, that Neose would be ****** for the Neose Project-Related Costs for   any additional work, by means of the ****** and/or the application of the   funding arrangements set forth in Section 2.3 of the Agreement.  Each Party shall be entitled to act in its   sole discretion in making such determination.
  

 ****** — Material has been omitted and filed separately with the Commission.

Neose Technologies, Inc.
 October 12, 2004
 Page 3

This letter amends the Agreement only as herein set forth and in all other respects the Agreement is ratified and confirmed.  Two originals of this letter amendment are enclosed in our Federal Express package, each of which has been executed on behalf of Novo. Please indicate the agreement of Neose with the terms of this letter by having this letter executed on behalf of the company in the space provided below, and return one fully executed copy to Novo Nordisk A/S by fax (+ 45 44 42 18 30) and Federal Express or DHL courier (each to the attention of Jannie Fuhlendorff, Scientific Licensing).

Sincerely yours,

Jannie Fuhlendorff
 Scientific Licensing
 Novo Nordisk A/S

ACCEPTED AND AGREED

	
  
NEOSE TECHNOLOGIES INC.
  	
  
 
  	
  
NOVO NORDISK A/S
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  By:
  	
  
/s/ ROBERT I. KRIEBEL
  	
  
 
  	
  
By:
  	
  
/s/ MADS KROGSGAARD THOMSEN
  
	
  
 
  	
  

  	
  
 
  	
  
 
  	
  

  
	
  
Name:
  	
  
Robert I.   Kriebel
  	
  
 
  	 Name:
	
  
Mads   Krogsgaard Thomsen
  
	
  
Title:
  	
  
Sr. Vice   President & CFO
  	
  
 
  	 Title:
	
  
Executive   Vice President
  
	
  November 9,   2004
  	
   
  	
   
  	
   
  

Neose Technologies, Inc.
 October 12, 2004
 Page 4

AMENDED EXHIBIT 2.2

******

 ****** — Material has been omitted and filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]